Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Saniona AB (publ)
  6. News
  7. Summary
    SANION   SE0005794617

SANIONA AB (PUBL)

(SANION)
  Report
Delayed Quote. Delayed Nasdaq Stockholm - 09/27 11:29:43 am
13.96 SEK   +0.14%
02:51aBIOSTOCK : áSaniona strengthens its board of directors
AQ
09/22BIOSTOCK : áSaniona's new CBO on strategy and business development
AQ
09/20SANIONA AB(OM : SANION) added to S&P Global BMI Index
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Saniona Receives U.S. FDA Orphan Drug Designation for Tesomet in Hypothalamic Obesity

07/26/2021 | 02:00am EDT

Saniona announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Tesomet for the treatment of hypothalamic obesity (HO). Tesomet is the first and only investigational treatment for HO to receive orphan drug designation. Saniona is preparing to initiate two Phase 2b studies of Tesomet in the second half of this year, one in HO and the other in Prader-Willi syndrome (PWS), for which Tesomet has already received orphan drug status. Orphan drug designation is a special status granted by the FDA to medicines and biologics that are intended for the treatment of rare diseases that affect fewer than 200,000 people in the U.S. The number of people living with HO is estimated to be between 10,000 and 25,000 in the U.S. and between 16,000 and 40,000 in Europe. Receiving orphan designation qualifies Saniona for certain development benefits, including tax credits, elimination of certain FDA license application fees, and seven years of market exclusivity in the U.S. following approval. Saniona previously evaluated Tesomet in a 24-week, double-blind, randomized, placebo-controlled initial Phase 2 trial in HO. Adults receiving Tesomet demonstrated statistically significant reductions in body weight and improvements in waist circumference and glycemic control. These improvements were maintained during an additional 24-week open-label extension. Tesomet was reported to be generally well-tolerated, and most adverse events were mild. The most common adverse events included sleep disorders, dizziness, dry mouth and headache. No clinically significant differences in heart rate or blood pressure were observed between the Tesomet-treated patients and the placebo-treated patients. In preparation for the initiation of the Phase 2b study of Tesomet in HO in the second half of 2021, Saniona has selected the clinical research organization (CRO) that will support the clinical trial and is in the process of assessing and selecting clinical trial sites in the U.S. and globally. Saniona has also selected the contract manufacturer to produce Tesomet for Phase 2b and Phase 3 clinical trials. Additionally, Saniona has initiated multiple partnerships with the HO advocacy community to incorporate caregiver and patient feedback into the clinical trial process and to provide the community with education on clinical trials. Saniona is also evaluating Tesomet for the treatment of Prader-Willi syndrome (PWS) and plans to begin a Phase 2b trial in this indication in the second half of this year. The FDA granted orphan drug designation to Tesomet for the treatment of PWS in March 2021.


ę S&P Capital IQ 2021
All news about SANIONA AB (PUBL)
02:51aBIOSTOCK : áSaniona strengthens its board of directors
AQ
09/22BIOSTOCK : áSaniona's new CBO on strategy and business development
AQ
09/20SANIONA AB(OM : SANION) added to S&P Global BMI Index
CI
09/16SANIONA : appoints Robert Hoffman to Board of Directors as Chair of the Audit Committee
AQ
09/16SANIONA : Bulletin from the Saniona AB extraordinary shareholders' meeting on September 16..
AQ
09/16Saniona AB Approves Appointment of Robert E. Hoffman as Board Member
CI
09/15SANIONA : appoints Wendy Dwyer as Chief Business Officer
AQ
09/15Saniona Appoints Wendy Dwyer as Chief Business Officer
CI
08/31BIOSTOCK : áSaniona's clinical and regulatory progress during H1
AQ
08/31Saniona Provides Clinical and Regulatory Progress
CI
More news
Financials
Sales 2020 8,20 M 0,94 M 0,94 M
Net income 2020 -73,4 M -8,44 M -8,44 M
Net cash 2020 526 M 60,5 M 60,5 M
P/E ratio 2020 -11,5x
Yield 2020 -
Capitalization 871 M 100 M 100 M
EV / Sales 2019 96,1x
EV / Sales 2020 92,5x
Nbr of Employees 50
Free-Float 86,0%
Chart SANIONA AB (PUBL)
Duration : Period :
Saniona AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SANIONA AB (PUBL)
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Managers and Directors
Rami Levin President & Chief Executive Officer
Jason A. Amello Chief Financial Officer
Joseph Donald DeBethizy Chairman
Palle Christophersen Chief Scientific Officer
Rudolf A. Baumgartner Chief Medical Officer & Head-Clinical Development
Sector and Competitors
1st jan.Capi. (M$)
SANIONA AB (PUBL)-32.33%100
GILEAD SCIENCES, INC.20.85%89 259
BIONTECH SE276.71%80 542
REGENERON PHARMACEUTICALS28.14%66 425
WUXI APPTEC CO., LTD.35.04%59 817
VERTEX PHARMACEUTICALS-22.40%47 634